Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

Calcort supply to end in Canada once remaining stock is gone, Duchenne groups say

Three patient organizations say Cheplapharm will stop supplying Calcort (deflazacort) once stock runs out. They are seeking details on what remains and exploring other sources.

2 min read4 sources
Share LinkedIn X Facebook Email
Illustrative photo accompanying this news article
Wheelchairs at a hospital entrance in Sweden, shown for illustration. Photo by W.carter via Wikimedia Commons (CC0). Image source Image source
In this article & details

Article details

Published
Nov 16, 2026
Reading time
2 min read
Categories
Drug Access, Drug Shortages
Jurisdiction
National
Sources cited
4
All news

Cheplapharm will stop supplying Calcort (deflazacort) to Canada once existing inventory is exhausted, three Duchenne muscular dystrophy organizations said on Nov. 11. Muscular Dystrophy Canada, Defeat Duchenne Canada and La Force DMD said they received written confirmation from the manufacturer, which cited problems with manufacturing and supply. Canada has historically received UK-labelled stock. Joint update

Patient groups seek details on remaining stock

The groups say they are working to establish which strengths remain available and how the stock will be distributed. They also want to identify other sources of deflazacort and determine what regulatory steps would be needed to make them accessible. Their Nov. 11 update gave no date for stock to run out. They directed families with questions about treatment changes to their treating clinicians, who can weigh clinical suitability, availability and cost. Access and continuity plans

Health Canada recorded 417 special-access requests in 2025

Health Canada lists Calcort among drugs accessed through its Special Access Program, which can make drugs unavailable for sale in Canada accessible on request. Its 2025 figures show 417 requests that led to access for Calcort tablets. The count measures requests rather than individual patients, and the listing itself does not establish current supply. Special Access Program data

Deflazacort is a corticosteroid used in Duchenne care. The three-year FOR-DMD randomized trial found better results on a combined measure of motor function, lung function and treatment satisfaction with either daily deflazacort or daily prednisone than with intermittent prednisone. The trial did not find a statistically significant difference between the two daily regimens on that measure. FOR-DMD trial

References

  1. Update on Calcort (deflazacort) availability in Canada — Muscular Dystrophy Canada, Defeat Duchenne Canada and La Force DMD, Joint update, Nov. 11, 2026
  2. Defeat Duchenne Canada: Joint update on Calcort (deflazacort) availability in Canada — Defeat Duchenne Canada, Joint update, Nov. 11, 2026
  3. Special access drugs: Most often requested — Health Canada, Jan. 1 to Dec. 31, 2025 data
  4. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial — Guglieri and colleagues, JAMA, FOR-DMD trial, April 2022

Discussion

0 comments

Join the discussion. Anyone can read the comments. To comment, log in or create a free individual account.

No comments yet.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.